Nuvation Bio is focused on treating patients with the most difficult-to-treat cancers for which conventional therapies have failed. We are advancing multiple compounds that have been generated from our drug discovery and development programs, which include a clinical stage bromodomain and extra-terminal (BET) inhibitor program and a novel, small molecule drug-drug conjugate (DDC) platform that to date has yielded investigational candidates targeting solid tumors.

potential indication(s)
Current Stage
phase 1
Phase 2
Phase 3
Solid Tumors
First Patient Dosed in Phase 1 Dose Escalation in Q1 2022
Ovarian, TNBC,
Pancreatic &
NUV-868 +
Dose First Patient by Year End 2022
NUV-868 +
Dose First Patient by Year End 2022
Select Clinical Candidate by Year End 2022
BET: Bromodomain and Extra-Terminal Motif Proteins; mCRPC: Metastatic Castration-Resistant Prostate Cancer; TNBC: Triple-Negative Breast Cancer


NUV-868, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor, inhibits BRD4. BRD4 is a key member of the BET family, which epigenetically regulates proteins that control tumor growth and differentiation.

NUV-868 is almost 1,500 times more selective for BD2 than BD1 and is designed to alleviate the therapeutic limiting toxicities observed by other non-BD2 selective BET inhibitors. NUV-868 in combination with androgen-receptor directed therapies may help to overcome resistance in prostate cancer. In addition, NUV-868 in combination with PARP inhibitors may act synergistically to increase efficacy across multiple solid tumors.

In March 2022, we initiated a Phase 1 dose escalation study of NUV-868 for the treatment of patients with advanced solid tumors and enrollment is ongoing. We expect to initiate the Phase 1b study of NUV-868 in combination with olaparib in ovarian, pancreatic, metastatic castration-resistant prostate and triple negative breast cancers, or in combination with enzalutamide in metastatic castration-resistant prostate cancer, by the end of 2022.

DDC Platform

Our proprietary, small molecule Drug-Drug Conjugate (DDC) platform leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies. The platform is designed to selectively deliver potent anti-cancer therapeutics to cancer cells to exert greater toxicity against these target tumor cells than against healthy non-target tissues.

Utilizing this platform, we are able to conjugate tissue-selective targeted small molecules with anti-tumor agents to create unique therapeutic candidates. We believe our DDC technology will be broadly applicable and can be replicated across many existing therapies to transform the standard-of-care in multiple oncology indications. We plan to select the first clinical candidate from our DDC platform by the end of 2022.